InsidersTradesSigma
Follow the TELA Bio, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, TELA Bio, Inc. has logged 15 public disclosures. Market capitalisation: €31.8m. The latest transaction was disclosed on 17 July 2026 (Attribution). Among the most active insiders: Capper Joseph H. All data is openly available.
15
Insider Decl.
n/a
Thresholds
€3m
1 ops.
Buy Volume
n/a
n/a
Sell Volume
26Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,012 of 29,064 companies
22.4
score / 100
Value1
Quality44
FCF yld-91%
Earn yld-124%
EV/EBITDA·
ROE·
Gross mgn68%
Net mgn-48%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 July 2026
Declarations15 total
6,227 shares@ US$0.7850.014% mcap100.0% of flowCommon StockSEC:0001456817-26-000011:0
20,930 shares@ US$0.7850.047% mcap100.0% of flowCommon StockSEC:0001685640-26-000003:0
11,925 sharesCommon StockSEC:0001456817-26-000009:0
11,675 sharesCommon StockSEC:0001456817-26-000009:1
86,000 shares0Common StockSEC:0002012926-26-000004:0
37,000 shares0Common StockSEC:0001984584-26-000002:0
32,850 shares0Common StockSEC:0001899973-26-000002:0
57,000 shares0Common StockSEC:0001899089-26-000002:0
57,000 shares0Common StockSEC:0001591474-26-000002:0
176,000 shares0Common StockSEC:0001195881-26-000002:0
3,604,000 shares@ US$1.11100.0% of flowCommon Stock, par value $0.001 per shareSEC:0000908834-25-000358:0
Canonical exit: 15 Feb 2026 (T+90)
11,925 shares0Common StockSEC:0001685640-25-000006:0
11,925 shares0Common StockSEC:0002089250-25-000004:0
1,093 shares@ US$1.86100.0% of flowCommon StockSEC:0001062993-25-013584:0
7,950 shares0Common StockSEC:0001062993-25-010569:0
15 of 15 declarations
关于 TELA Bio, Inc.
TELA Bio, Inc. 是一家美国医疗技术公司，在美国 NASDAQ 市场上市。该公司专注于创新软组织重建解决方案，旨在支持手术修复和重建，同时优先保护患者自身解剖结构。TELA Bio 总部位于宾夕法尼亚州马尔文，主要在美国市场开展商业活动，国际业务规模较小。([ir.telabio.com](https://ir.telabio.com/news-releases/news-release-details/tela-bio-reports-fourth-quarter-and-full-year-2025-financial/)) 该公司成立于 2012 年，围绕软组织重建生物材料平台而建立。其产品组合最初专注于腹壁重建和疝气修复，后来扩展至整形和重建手术领域。主要产品包括用于软组织重建和疝气修复的 OviTex，以及针对整形和重建手术应用的 OviTex PRS。TELA Bio 还获得了 FDA 510(k) 许可，用于 Restella 等产品系列以及特定 OviTex PRS 配置，这些许可支持了更广泛的商业采用。([ir.telabio.com](https://ir.telabio.com/news-releases/news-release-details/tela-bio-announces-510k-clearance-ovitexr-prs-long-term)) 从竞争角度来看，TELA Bio 是一家专业化企业，而非大型多元化医疗器械平台。其差异化优势来自生物材料设计、临床证据和针对医院手术医生的专注商业模式的结合。在竞争激烈的软组织重建市场中，该公司通过产品性能、扩展规格/配置和更深入的商业渗透来寻求市场份额增长。与此同时，该业务仍然面临常见的医疗器械风险：报销动态、临床采用、定价压力、持续证据生成的需要以及销售队伍投资的持续需求。([sec.gov](https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm)) 最近的发展表明增长势头良好，但该业务尚未实现盈利。在 2025 年第二季度，TELA Bio 报告收入为 $20.2 million，同比增长 26%，其中 OviTex PRS 增长尤为强劲。2026 年 3 月，该公司表示 2025 年以创纪录的季度收入 $20.9 million 在 Q4 2025 收盘，同时全年运营支出基本持平。2026 年初，管理层还宣布了战略性董事会改组，旨在加快增长并支持实现盈利的路径。对于投资者而言，TELA Bio 仍然是 NASDAQ 上的利基医疗器械增长股，具有吸引力的商业潜力，但持续存在执行和盈利风险。([ir.telabio.com](https://ir.telabio.com/news-releases/news-release-details/tela-bio-reports-second-quarter-2025-financial-results))
